Belinostat moves into its first randomized trial in combination with 5-Aza for cancer patients suffering from AML or MDS

Announcement No. 01-09 / Copenhagen, 6 January 2009

Copenhagen, Denmark, 6 January 2009 - TopoTarget A/S (OMX: TOPO) announces that
belinostat has moved into the randomized portion of a study in patients with
hematologic malignancies where patients with Myelodysplastic Syndrome (MDS) or
Acute Myelogenous Leukaemia (AML) will be treated. Patients will receive
treatment with belinostat + 5-Azacytidine (experimental group) or 5-Azacytidine
monotherapy (control group). The study is sponsored by the Cancer Therapy
Evaluation Program at the National Cancer Institute (NCI, US) under a Clinical
Trials Agreement with TopoTarget for the development of belinostat. 

“Belinostat and 5-Azacytidine open silenced genes by different routes and the
combination is synergistic in several cancer models” said Professor Peter Buhl
Jensen, MD and CEO of TopoTarget. “We look very much forward to see the data
from this next randomized portion of the study”. 

For further information, please contact:

Ulla Hald Buhl 	                  Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49

For further information about TopoTarget see www.topotarget.com